Follow
Carol Aghajanian, MD
Carol Aghajanian, MD
Chief, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center
Verified email at mskcc.org - Homepage
Title
Cited by
Cited by
Year
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
K Moore, N Colombo, G Scambia, BG Kim, A Oaknin, M Friedlander, ...
New England Journal of Medicine 379 (26), 2495-2505, 2018
24402018
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial …
C Aghajanian, SV Blank, BA Goff, PL Judson, MG Teneriello, A Husain, ...
Journal of clinical oncology 30 (17), 2039, 2012
16612012
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
16182017
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
ML Hensley, R Maki, E Venkatraman, G Geller, M Lovegren, ...
Journal of Clinical Oncology 20 (12), 2824-2831, 2002
8152002
Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer
RL Coleman, GF Fleming, MF Brady, EM Swisher, KD Steffensen, ...
New England Journal of Medicine 381 (25), 2403-2415, 2019
7862019
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
DS Chi, EL Eisenhauer, O Zivanovic, Y Sonoda, NR Abu-Rustum, ...
Gynecologic oncology 114 (1), 26-31, 2009
6922009
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
C Aghajanian, S Soignet, DS Dizon, CS Pien, J Adams, PJ Elliott, ...
Clinical cancer research 8 (8), 2505-2511, 2002
6122002
The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center
NR Abu-Rustum, K Alektiar, A Iasonos, G Lev, Y Sonoda, C Aghajanian, ...
Gynecologic oncology 103 (2), 714-718, 2006
4662006
Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient
A Jiménez-Sánchez, D Memon, S Pourpe, H Veeraraghavan, Y Li, ...
Cell 170 (5), 927-938. e20, 2017
4492017
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer
V Makker, MH Taylor, C Aghajanian, A Oaknin, J Mier, AL Cohn, ...
Journal of clinical oncology 38 (26), 2981-2992, 2020
4432020
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
V Makker, D Rasco, NJ Vogelzang, MS Brose, AL Cohn, J Mier, ...
The Lancet Oncology 20 (5), 711-718, 2019
4392019
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma
DS Chi, K McCaughty, JP Diaz, J Huh, S Schwabenbauer, AJ Hummer, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2006
4362006
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer
EL Eisenhauer, NR Abu-Rustum, Y Sonoda, DA Levine, EA Poynor, ...
Gynecologic oncology 103 (3), 1083-1090, 2006
4172006
Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer
KS Tewari, RA Burger, D Enserro, BM Norquist, EM Swisher, MF Brady, ...
Journal of Clinical Oncology 37 (26), 2317, 2019
3982019
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
C Aghajanian, MW Sill, KM Darcy, B Greer, DS McMeekin, PG Rose, ...
Journal of clinical oncology 29 (16), 2259, 2011
3712011
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
C Aghajanian, B Goff, LR Nycum, YV Wang, A Husain, SV Blank
Gynecologic oncology 139 (1), 10-16, 2015
3492015
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients
P Sabbatini, T Tsuji, L Ferran, E Ritter, C Sedrak, K Tuballes, ...
Clinical cancer research 18 (23), 6497-6508, 2012
3222012
Identification of six new susceptibility loci for invasive epithelial ovarian cancer
KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ...
Nature genetics 47 (2), 164-171, 2015
3102015
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
D Fennelly, C Aghajanian, F Shapiro, C O'flaherty, M McKenzie, ...
Journal of Clinical Oncology 15 (1), 187-192, 1997
3091997
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
SM Domchek, C Aghajanian, R Shapira-Frommer, RK Schmutzler, ...
Gynecologic oncology 140 (2), 199-203, 2016
3052016
The system can't perform the operation now. Try again later.
Articles 1–20